Thank you - Your Download is Available Below
The New Economics of Biologics: Breaking the $50/g Barrier — Now
Monoclonal antibodies (mAbs) are the backbone of modern biologics, representing the majority of mammalian biomanufacturing capacity and clinical impact. However, manufacturing costs continue to limit broader access.
This report demonstrates that reaching manufacturing costs below ~$50/g will require a step change in how processes are designed and operated — shifting from incremental improvements to more fundamental transformation across the entire workflow.
Learn why conventional batch manufacturing approaches a $50 – 100/g cost floor
Explore how coordinated intensification strategies can reduce mAb production costs
Compare cost-modeling results across processing scenarios and demand levels
